Apollo signs $500,000 deal with Symansis
Wednesday, 11 June, 2008
Suspended Sydney biotech Apollo Life Sciences (ASX: AOP) has sold a proportion of its non-core assets to New Zealand antibody specialist Symansis for $500,000.
The parties have also signed a short-term supply contract.
The deal also allows Symansis to license some of Apollo's proprietary techniques to assist in the manufacture of proteins for sale as research reagents.
The parties have also entered into a supply contract, whereby Apollo has also agreed to manufacture and supply specified proteins to Symansis.
In a statement, Apollo's CEO John Priest said the company is currently consolidating its operations and intends to focus on its core research activities, including its oral and transdermal delivery sytems and its portfolio of human-expressed proteins.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
